BackCellectis Overview

Cellectis Receivables

Cellectis's receivables is $15M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$15.05M
41.03% YoYΔ $-10.47M vs prior year quarter

Peer average

Loading

Cellectis Receivables History

Loading

Cellectis vs. peers: Receivables Comparison

Loading

Cellectis Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cellectis (CLLS) FAQ

The latest receivables for CLLS is $15M as of March 2026. That compares with $26M in the prior-year period — down 41.0% year over year. Investors often review this figure alongside Cellectis's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLLS's receivables moved from $26M to $15M — a 41.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cellectis's operating scale or balance-sheet position.

A receivables figure of $15M for CLLS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CLLS's receivables ($15M), review year-over-year change from $26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cellectis's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.